EGFR and head and neck squamous cell carcinoma: In this regard, increased levels of phospho-Akt following cetuximab treatment [17] and elevated mTOR activity [18] have been reported in HNSCC resistance studies, although their precise role in anti-EGFR resistance remains largely unclear.